Time trends in statin utilization and coronary mortality in western European countries

Frederico Vancheri, Lars Backlund, Lars-Erik Strender, Brian Godman, Bjorn Wettermark

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objectives. To determine whether there is a relation between statin utilization and coronary heart disease (CHD) mortality in populations with different levels of coronary risk, and whether the relation changes over time. Design. Ecological study using national databases on dispensed medicines and mortality rates. Setting. Western European countries with similar public health systems. Main outcome measures. Population CHD mortality rates (rate/100.000) as a proxy for population coronary risk level, and statin utilization expressed as Defined Daily Dose per one Thousand Inhabitants per Day (DDD/TID), in each country, for each year between 2000 and 2012. Pearson’s correlation coefficients between CHD mortality and statin utilization were calculated. Linear regression analysis was used to assess the relation between changes in CHD mortality and statin utilization over the years. Results. Twelve countries were included in the study. There was a wide range of CHD mortality reduction between the years 2000 and 2012 (from 25.9% in Italy to 57.9% in Denmark) and statin utilization increase (from 121% in Belgium to 1,263% in Denmark). No statistically significant relations were found between CHD mortality rates and statin utilization, nor between changes in CHD and changes in statin utilization in the countries over the years 2000 and 2012. Conclusions. Among the Western European countries studied, the large increase in statin utilization between 2000 and 2012 was not associated with CHD mortality, nor with its rate of change over the years. Factors different from the individual coronary risk, such as population ageing, health authority programs, guidelines, media attention and pharmaceutical industry marketing, may have influenced the large increase in statin utilization. These need to be re-examined with a greater emphasis on prevention strategies.
LanguageEnglish
Pagese010500
Number of pages8
JournalBMJ Open
Volume6
Issue number3
DOIs
Publication statusPublished - 30 Mar 2016

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Coronary Disease
Mortality
Denmark
Population
Belgium
Drug Industry
Proxy
Marketing
Italy
Linear Models
Public Health
Regression Analysis
Outcome Assessment (Health Care)
Databases
Guidelines

Keywords

  • coronary heart disease
  • coronary mortality
  • statin utilization

Cite this

Vancheri, Frederico ; Backlund, Lars ; Strender, Lars-Erik ; Godman, Brian ; Wettermark, Bjorn . / Time trends in statin utilization and coronary mortality in western European countries. In: BMJ Open. 2016 ; Vol. 6, No. 3. pp. e010500.
@article{3d77c6eb4948462d9a56596155f8db7f,
title = "Time trends in statin utilization and coronary mortality in western European countries",
abstract = "Objectives. To determine whether there is a relation between statin utilization and coronary heart disease (CHD) mortality in populations with different levels of coronary risk, and whether the relation changes over time. Design. Ecological study using national databases on dispensed medicines and mortality rates. Setting. Western European countries with similar public health systems. Main outcome measures. Population CHD mortality rates (rate/100.000) as a proxy for population coronary risk level, and statin utilization expressed as Defined Daily Dose per one Thousand Inhabitants per Day (DDD/TID), in each country, for each year between 2000 and 2012. Pearson’s correlation coefficients between CHD mortality and statin utilization were calculated. Linear regression analysis was used to assess the relation between changes in CHD mortality and statin utilization over the years. Results. Twelve countries were included in the study. There was a wide range of CHD mortality reduction between the years 2000 and 2012 (from 25.9{\%} in Italy to 57.9{\%} in Denmark) and statin utilization increase (from 121{\%} in Belgium to 1,263{\%} in Denmark). No statistically significant relations were found between CHD mortality rates and statin utilization, nor between changes in CHD and changes in statin utilization in the countries over the years 2000 and 2012. Conclusions. Among the Western European countries studied, the large increase in statin utilization between 2000 and 2012 was not associated with CHD mortality, nor with its rate of change over the years. Factors different from the individual coronary risk, such as population ageing, health authority programs, guidelines, media attention and pharmaceutical industry marketing, may have influenced the large increase in statin utilization. These need to be re-examined with a greater emphasis on prevention strategies.",
keywords = "coronary heart disease, coronary mortality, statin utilization",
author = "Frederico Vancheri and Lars Backlund and Lars-Erik Strender and Brian Godman and Bjorn Wettermark",
year = "2016",
month = "3",
day = "30",
doi = "10.1136/bmjopen-2015-010500",
language = "English",
volume = "6",
pages = "e010500",
journal = "BMJ Open",
issn = "2044-6055",
number = "3",

}

Time trends in statin utilization and coronary mortality in western European countries. / Vancheri, Frederico; Backlund, Lars; Strender, Lars-Erik; Godman, Brian; Wettermark, Bjorn .

In: BMJ Open, Vol. 6, No. 3, 30.03.2016, p. e010500.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Time trends in statin utilization and coronary mortality in western European countries

AU - Vancheri, Frederico

AU - Backlund, Lars

AU - Strender, Lars-Erik

AU - Godman, Brian

AU - Wettermark, Bjorn

PY - 2016/3/30

Y1 - 2016/3/30

N2 - Objectives. To determine whether there is a relation between statin utilization and coronary heart disease (CHD) mortality in populations with different levels of coronary risk, and whether the relation changes over time. Design. Ecological study using national databases on dispensed medicines and mortality rates. Setting. Western European countries with similar public health systems. Main outcome measures. Population CHD mortality rates (rate/100.000) as a proxy for population coronary risk level, and statin utilization expressed as Defined Daily Dose per one Thousand Inhabitants per Day (DDD/TID), in each country, for each year between 2000 and 2012. Pearson’s correlation coefficients between CHD mortality and statin utilization were calculated. Linear regression analysis was used to assess the relation between changes in CHD mortality and statin utilization over the years. Results. Twelve countries were included in the study. There was a wide range of CHD mortality reduction between the years 2000 and 2012 (from 25.9% in Italy to 57.9% in Denmark) and statin utilization increase (from 121% in Belgium to 1,263% in Denmark). No statistically significant relations were found between CHD mortality rates and statin utilization, nor between changes in CHD and changes in statin utilization in the countries over the years 2000 and 2012. Conclusions. Among the Western European countries studied, the large increase in statin utilization between 2000 and 2012 was not associated with CHD mortality, nor with its rate of change over the years. Factors different from the individual coronary risk, such as population ageing, health authority programs, guidelines, media attention and pharmaceutical industry marketing, may have influenced the large increase in statin utilization. These need to be re-examined with a greater emphasis on prevention strategies.

AB - Objectives. To determine whether there is a relation between statin utilization and coronary heart disease (CHD) mortality in populations with different levels of coronary risk, and whether the relation changes over time. Design. Ecological study using national databases on dispensed medicines and mortality rates. Setting. Western European countries with similar public health systems. Main outcome measures. Population CHD mortality rates (rate/100.000) as a proxy for population coronary risk level, and statin utilization expressed as Defined Daily Dose per one Thousand Inhabitants per Day (DDD/TID), in each country, for each year between 2000 and 2012. Pearson’s correlation coefficients between CHD mortality and statin utilization were calculated. Linear regression analysis was used to assess the relation between changes in CHD mortality and statin utilization over the years. Results. Twelve countries were included in the study. There was a wide range of CHD mortality reduction between the years 2000 and 2012 (from 25.9% in Italy to 57.9% in Denmark) and statin utilization increase (from 121% in Belgium to 1,263% in Denmark). No statistically significant relations were found between CHD mortality rates and statin utilization, nor between changes in CHD and changes in statin utilization in the countries over the years 2000 and 2012. Conclusions. Among the Western European countries studied, the large increase in statin utilization between 2000 and 2012 was not associated with CHD mortality, nor with its rate of change over the years. Factors different from the individual coronary risk, such as population ageing, health authority programs, guidelines, media attention and pharmaceutical industry marketing, may have influenced the large increase in statin utilization. These need to be re-examined with a greater emphasis on prevention strategies.

KW - coronary heart disease

KW - coronary mortality

KW - statin utilization

UR - http://bmjopen.bmj.com/

U2 - 10.1136/bmjopen-2015-010500

DO - 10.1136/bmjopen-2015-010500

M3 - Article

VL - 6

SP - e010500

JO - BMJ Open

T2 - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 3

ER -